High prices for combination regimens will translate to high revenues, despite the introduction of generics in the mid-term future. The increased use of Trikafta will offset the decrease in revenues caused by generics over the forecast period. 

The first CFTR modulator triplet, Trikafta, is approved in patients with at least one F508del mutation regardless of their second mutation. Despite its late approval, Trikafta is the only CFTR modulator approved for F508del heterozygous patients, and its substantial improvement in lung function over both Symdeko and Orkambi in F508del homozygous patients has allowed it to capture the majority of the CF patient population. 

In February 2024, pivotal trial results of Vanza Triple revealed that it is comparable to Trikafta in improving lung function and surpasses Trikafta in reducing sweat chloride levels. As a result, the market dominance of Trikafta is expected to be challenged, particularly because Vanza Triple offers the advantage of once-daily dosing and will benefit from Vertex's expertise in the CFTR modulator market

This Datamonitor Healthcare report contains a Disease Analysis module.